Skip to content

Research on the Effects of the Novel Analgesic Tegileridine on Perioperative Neurocognitive Function and Its Mechanisms

Research on the Effects of the Novel Analgesic Tegileridine on Perioperative Neurocognitive Function and Its Mechanisms

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114396
Enrollment
Unknown
Registered
2025-12-11
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Tegileridine Group:Fifteen minutes before the end of surgery, 1 mg of tigecycline was administered intravenously. The PCIA solution was prepared by diluting 10 mg of tigecycline and 9 mg of granisetro
Control Group:Fifteen minutes before the end of surgery, 10 mg of morphine was administered intravenously. The PCIA solution was prepared by diluting 100 mg of morphine and 9 mg of granisetron to a to

Sponsors

Jiangsu Province People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients and their family members consent to participate in this study; (2) Patients scheduled for elective gastric or colorectal cancer surgery who consent to use a patient-controlled analgesia (PCA) pump postoperatively; (3) Age range of 65 to 80 years old; (4) Patients without severe hearing or visual impairments and who are literate.

Exclusion criteria

Exclusion criteria: (1) Patient or family members refuse to participate in the study; (2) History of ischemic stroke or transient ischemic attack (TIA); (3) History of myocardial infarction, or NYHA heart function classification of Class II or higher; (4) History of psychiatric disorders (e.g., schizophrenia, depression), cognitive impairment, epilepsy, or Parkinson's syndrome; (5) Abnormal liver function during the screening period: aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 × ULN and/or total bilirubin (TBIL) > 1.5 × ULN; (6) Abnormal renal function during the screening period: serum creatinine (Cr) > 1.5 × ULN; (7) Mini-Mental State Examination (MMSE) score below 23; (8) Current use of sedatives, antidepressants, or corticosteroids; (9) Alcoholism or substance abuse; (10) Inability to read, write, hear, speak, or communicate effectively.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium (POD);

Secondary

MeasureTime frame
Incidence of delayed neurocognitive recovery ;Incidence of neurocognitive disorders (NCD);Postoperative pulmonary complications;Gastrointestinal reactions;VAS pain scores at 24 and 48 hours postoperatively;Incidence of rescue analgesia;Number of PCA bolus attempts;Consumption of Tegileridine or morphine;

Countries

China

Contacts

Public ContactChun Yang

Jiangsu Province People's Hospital

dr.analgesia@qq.com+86 186 2781 6797

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026